XPhyto (CSE: XPHY-OTC: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive to bring news their exclusive diagnostic partner, 3a-Diagnostics is developing a reverse transcription-polymerase chain reaction kit targeting COVID-19 with results in 25 minutes.
Rogers telling Proactive they are planning two test kits and they expect to launch them in the European market in Q-1 2021.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE